Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
Alimentary Pharmacology & Therapeutics · 2024-08 · 60 (3) · 327-339
DOI: 10.1111/apt.18063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.06.2024. Verfasst von Shusuke Kumazaki und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Liver Neoplasms, Liver Cirrhosis, Biomarkers. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background and Aims Although metabolic dysfunction‐associated steatotic liver disease (MASLD) patients with a Fib‐4 index >1.3 are recommended for fibrosis evaluation via elastography or biopsy, a more convenient method identifying high‐risk populations requiring follow‐up is needed. We explored the utility of serum levels of growth differentiation factor‐15 (GDF15), a cell stress‐responsive cytokine related to metabolic syndrome, for stratifying the risk of clinical events in MASLD patients.
Methods
Serum GDF15 levels were measured in 518 biopsy‐performed MASLD patients, 216 MASLD patients for validation, and 361 health checkup recipients with MASLD.
Results
In the biopsy‐MASLD cohort, multivariate analysis indicated that the serum GDF15 level was a risk factor for liver cancer, independent of the fibrosis stage or Fib‐4 index. Using a GDF15 cutoff of 1.75 ng/mL based on the Youden index, high‐GDF15 patients, regardless of fibrosis status, had a higher liver cancer incidence rate. While patients with a Fib‐4 index 1.3 developed liver cancer and decompensated liver events at significantly higher rates and had poorer prognoses. In the validation cohort, high‐GDF15 patients had significantly higher incidences of liver cancer and decompensated liver events and poorer prognoses than low‐GDF15 patients, whether limited to high‐Fib‐4 patients. Among health checkup recipients with MASLD, 23.0% had a Fib‐4 index >1.3, 2.7% had a Fib‐4 index >1.3 and >1.75 ng/mL GDF15.
Conclusions
Serum GDF15 is a biomarker for liver cancer with high predictive capability and is useful for identifying MASLD patients requiring regular surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Kaizuka City Hospital, Osaka, Japan.
- Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Hidenori Toyoda, Goki Suda, Tetsuo Takehara
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Kumazaki, S., Hikita, H., Tahata, Y., Sung, J. H., Fukumoto, K., Myojin, Y., Sakane, S., Murai, K., Sasaki, Y., Shirai, K., Saito, Y., Kodama, T., Kakita, N., Takahashi, H., Toyoda, H., Suda, G., Morii, E., Kojima, T., Ebihara, T., …, & Takehara, T. (2024). Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Alimentary Pharmacology & Therapeutics, 60(3), 327-339. https://doi.org/10.1111/apt.18063
Vancouver
Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Alimentary Pharmacology & Therapeutics. 2024;60(3):327-339. doi:10.1111/apt.18063
BibTeX
@article{Kumazaki2024,
author = {Kumazaki, Shusuke and Hikita, Hayato and Tahata, Yuki and Sung, Ji Hyun and Fukumoto, Kenji and Myojin, Yuta and Sakane, Sadatsugu and Murai, Kazuhiro and Sasaki, Yoichi and Shirai, Kumiko and Saito, Yoshinobu and Kodama, Takahiro and Kakita, Naruyasu and Takahashi, Hirokazu and Toyoda, Hidenori and Suda, Goki and Morii, Eiichi and Kojima, Takashi and Ebihara, Takeshi and Shimizu, Kentaro and Sasaki, Yutaka and Tatsumi, Tomohide and Takehara, Tetsuo},
title = {Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {3},
pages = {327--339},
doi = {10.1111/apt.18063}
}
EUVIMED